miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome
NCT02418195
Completed
The purpose of this study is to examine whether neural-derived exosomal miRNAs are differentially expressed that are specific to suicidal ideation or behavior, and which by affecting specific miRNA targets and pathways, are associated with suicidal behavior and response to ketamine. The following groups of subjects will be examined: 1) major depressive disorder (MDD) with a recent suicide attempt (in past 2 weeks), 2) MDD with serious ideation (in the past 7 days) without recent suicide attempt... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/03/2022
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Major Depressive Disorder
Register for Updates
IN Sub-Dissociative Ketamine vs IN Fentanyl
NCT02521415
Completed
This single center, randomized control, double blind trial will prospectively examine the feasibility of intranasal, sub-dissociative (IN) ketamine versus intranasal fentanyl for pain control in the pediatric emergency department setting. The investigators hypothesize that IN ketamine may provide a safe and effective alternative to IN fentanyl for children with suspected, isolated extremity fractures. Eighty children ages 3-17 years with a suspected, isolated extremity fracture that requires an... Read More
Gender:
ALL
Ages:
Between 4 years and 17 years
Trial Updated:
06/30/2022
Locations: Carolinas Medical Center Main - Levine Children's Hospital Emergency Department, Charlotte, North Carolina
Conditions: Bone Fracture
Register for Updates
Nebulized Sub-dissociative Dose Ketamine for Treating Pain
NCT03909607
Completed
The investigators previous research study comparing the efficacy of intravenous ketamine to morphine showed ketamine to provide equivalent relief of moderate to severe acute pain in emergency department patients. A second study by the investigators showed that increasing the time of administration of the ketamine, from a push injection to a drip infusion, will minimize the adverse effects experienced by recipients of ketamine. The investigators now aim to see if nebulized subdissociative-dose k... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/26/2022
Locations: Maimonides Medical Center, Brooklyn, New York
Conditions: Pain
Register for Updates
Ketamine and Magnesium in Post-operative Pain Control in Patients Treated With Opioids
NCT02940509
Terminated
The goal of this research proposal is to determine if the intraoperative administrative of Ketamine and Magnesium during laparoscopic gynecologic surgery improves postoperative pain in patients on chronic opioid therapy for management of chronic pelvic pain.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
05/24/2022
Locations: Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Chronic Pain
Register for Updates
CAP-Ketamine for Antidepressant Resistant PTSD
NCT02655692
Completed
The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/06/2022
Locations: VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut +2 locations
Conditions: PTSD, Posttraumatic Stress Disorder
Register for Updates
Use of Transmucosal Ketamine in Post Stroke Depression
NCT04876066
Unknown
Studies have shown that ketamine is very effective and has a quick onset in treatment of depression. Most of these studies used intravenous ketamine in an inpatient setting and there are no large trials examining its use in Post Stroke Depression (PSD). There have been only few studies that have used other routes of administration (i.e., oral, transmucosal, intranasal, intramuscular) of ketamine which provided symptom relief for depression. The purpose of this study is to assess the effectivenes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2022
Locations: WVU Medicine, Morgantown, West Virginia
Conditions: Post-stroke Depression
Register for Updates
Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash
NCT01566448
Completed
Oral mucositis (inflammation of the lining of the mouth) is a very common adverse effect when chemotherapy and radiation therapy are used to treat cancer. Mucositis occurs in about 40% of patients receiving standard dose chemotherapy, 80% of patients receiving radiation therapy of the head and neck, and up to 100% of patients undergoing a bone marrow transplant. Because the pain from mucositis can be so bad it can cause the inability to eat or drink, inability to talk, gagging and drooling. Many... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2022
Locations: West Virginia University Hospitals Mary Babb Randolph Cancer Center, Morgantown, West Virginia
Conditions: Mucositis
Register for Updates
Comparison of Low-dose Ketamine to Opioids in the Management of Acute Pain in Patients Presenting to the Emergency Department With Long Bone Fractures
NCT04061330
Withdrawn
The purpose of this study is to establish the feasibility of initiating a ketamine pain control protocol in the emergency department for the treatment of acute pain in patients with long bone fractures and to compare the efficacy of the ketamine pain protocol to bolus morphine for pain control in the first 6 hours of patient stay in the emergency department.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/19/2022
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Pain, Acute
Register for Updates
Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects
NCT04173962
Completed
The objective of this study is to examine the effect of a single IV dose of ketamine (0.5 mg/kg) on laboratory-induced stress in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
04/18/2022
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Healthy Volunteers
Register for Updates
Intramuscular Ketamine for Suicidal Ideation
NCT05105061
Withdrawn
The objective of the present research protocol, a cross-over, subject-blinded, clinical trial, is to correlate changes in brain activity with reduction in suicidal ideation in response to a single intramuscular dose of ketamine. While ketamine is increasingly used as a rapid, antidepressant agent, there is accumulating evidence of additional anti-suicidal properties that may be distinct from its effects on depression. This pilot study will be used to determine (1) whether specific electroencepha... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2022
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Suicidal Ideation
Register for Updates
Ketamine Versus Fentanyl for Surgical Abortions
NCT04871425
Completed
Ketamine is commonly used for procedural sedation and analgesia. It is widely used for trauma cases in the emergency department and is considered a superior agent in the outpatient setting due to its lack of respiratory and cardiovascular depression. In chronic opioid users, ketamine decreases acute pain and reduces postoperative opioid consumption. Few studies have examined the use of ketamine for surgical abortions. Previous studies found significant rates of emergence phenomena; however, this... Read More
Gender:
FEMALE
Ages:
14 years and above
Trial Updated:
03/22/2022
Locations: Cedar River Clinic, Renton, Washington
Conditions: Abortion in First Trimester, Pain, Procedural, Opioid Use
Register for Updates
Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects
NCT00700076
Completed
Org 25935 is a new putative antipsychotic agent developed by N.V. Organon.The primary objective of this study is to investigate the effect of Org 25935 on ketamine-induced impairments in immediate recall.
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
03/02/2022
Locations: Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut
Conditions: Healthy
Register for Updates